ArticleBlood advances2025

Long-term outcomes of genome-edited "universal" CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center.

Daniela Guardo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.